The 31 references in paper O. Reshet'ko V., K. Lutsevich A., О. Решетько В., К. Луцевич А. (2018) “Фармакоэкономика как инструмент клинической фармакологии для оптимизации фармакотерапии (обзор) // Pharmacoeconomics as an instrument of clinical pharmacology for optimization of pharmacotherapy (review)” / spz:neicon:vedomostincesmp:y:2015:i:4:p:54-57

1
Ritter JM. Money makes the world go round: the pervasiveness of pharmacoeconomics. Br J Clin Pharmacol. 2008; 66: 755–7.
(check this in PDF content)
2
Drummond M. Pharmacoeconomics: friend or foe? Ann Rheum Dis 2006; 65 (Suppl. III): iii44–iii47.
(check this in PDF content)
3
Pang F. Design, analysis and presentation of multinational economic studies. The need for guidance. Pharmacoeconomics 2002; 20: 75–90.
(check this in PDF content)
4
Petrov VI. Pharmacoepidemiology and pharmacoeconomics in Russia: the status of the problems and prospects of development. Klinicheskie issledovanija lekarstv v Rossii 2002; (1): 8-10 (in Russian).
(check this in PDF content)
5
Edlin R, Round J, Hulme C, McCabe C. Cost effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. Br J Clin Pharmacol. 2010; 70: 350–355.
(check this in PDF content)
6
Mohan L, Kumari KM, Dikshit H, Biswas NR. Pharmacoeconomic exercise for undergraduate medical students. Int J Basic Clin Pharmacol. 2014; 3: 1099– 1100.
(check this in PDF content)
7
Kulkarni U, Deshmukh YA, Moghe VV, Rege N, Kate M. Introducing pharmacoeconomics (PE) in medical undergraduate curriculum. Afr J Pharm Pharmacol. 2010; 4: 27–30.
(check this in PDF content)
8
Babar ZU, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28: 1069–74.
(check this in PDF content)
9
Singh J. International society for pharmacoeconomics and outcomes research. Indian J Pharmacol. 2006; 38: 376–7.
(check this in PDF content)
10
Lyles A. Recent trends in pharmacoeconomics: Needs and unmet needs. Eur J Pharm Sci 2008; 34: S7-S24.
(check this in PDF content)
11
Brazier J. Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 2008; 26: 769–79. R E F E R E N C E S 1. Ritter JM. Money makes the world go round: the pervasiveness of 56
(check this in PDF content)
12
Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, et al. Transferability 12. Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, et al. Transferability of of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009; (12): 409–18.
(check this in PDF content)
13
Bodrogi J, Kalo Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol. 2010; 159: 1367–73.
(check this in PDF content)
14
Honig PK, Lalonde R. The economics of drug development: a grim reality and a role for clinical pharmacology. Clin Pharmacol Ther. 2010; 87: 247–51.
(check this in PDF content)
15
Honig PK. Comparative effectiveness: The fourth hurdle in drug development and a role for clinical pharmacology. Clin Pharmacol Ther. 2011; 89: 151–6.
(check this in PDF content)
16
Krammer H. Pharmacoeconomic analyses – chance or 4th hurdle for innovative drugs. Wien Med Wochenschr 2006; 156: 606–11.
(check this in PDF content)
17
Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 2002; 20 (Suppl. 3): 11–29.
(check this in PDF content)
18
Robertson J, Lang D, Hill S. Use of pharmacoeconomics in prescribing research. Part 1: costs-moving beyond the acquisition price for drugs. J Clin Pharm Ther. 2003; 28: 73–9.
(check this in PDF content)
19
Newby D, Hill S. Use of pharmacoeconomics in prescribing research. Part 2: cost-minimization analysis – when are two therapies equal? J Clin Pharm Ther. 2003; 28: 145–50.
(check this in PDF content)
20
Lopert R, Lang DL, Hill S. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis – a technique for decision-making at the margin. J Clin Pharm Ther. 2003; 28: 243–9.
(check this in PDF content)
21
Brinsmead R, Hill S. Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool? J Clin Pharm Ther. 2003; 28: 339–46.
(check this in PDF content)
22
McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000; 17: 501–13.
(check this in PDF content)
23
Khanna D, Tsevat J. Health-related Quality of Life – an introduction. Am J Managed Care 2007; 13: S218-S223.
(check this in PDF content)
24
Vemer P, Rutten-van Molken MPMH. Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. Eur J Health Econ. 2011; 12: 397–404.
(check this in PDF content)
25
Hughes D. An agenda for UK clinical pharmacology. Pharmacoeconomics. Br J Clin Pharmacol. 2012; 73: 968–72.
(check this in PDF content)
26
Hughes D, Reynolds DJ. Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees. Clin Med. 2009; 9: 490–2.
(check this in PDF content)
27
Rohilla A, Kumar A, Keshari R, et al. Pharmacoeconomics: An overview. International Journal of Research in Pharmacy and Chemistry 2013; 3: 64–8.
(check this in PDF content)
28
Waldman SA, Terzic A. Pharmacoeconomics in the era of individualized medicine. Clin Pharmacol Ther. 2008; 84: 179–82.
(check this in PDF content)
29
Iram M, Rani S, Hiremath R. Pharmacoeconomics: Need for the day. Indian J Pharm Pract. 2009; 2: 16–18.
(check this in PDF content)
30
Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis GJ, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26: 569–87.
(check this in PDF content)
31
Petrov VI, Sabanov AV. Pharmacoeconomic studies in the Russian health care system. Klinicheskie issledovanija lekarstv v Rossii 2004; (1): 7 (in Russian). economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009; (12): 409–18. 13. Bodrogi J, Kalo Z. Principles of pharmacoeconomics and their impact on str
(check this in PDF content)